Containment of COVID-19 in Ethiopia and implications for tuberculosis care and research.


Journal

Infectious diseases of poverty
ISSN: 2049-9957
Titre abrégé: Infect Dis Poverty
Pays: England
ID NLM: 101606645

Informations de publication

Date de publication:
16 Sep 2020
Historique:
received: 18 05 2020
accepted: 08 09 2020
entrez: 17 9 2020
pubmed: 18 9 2020
medline: 25 9 2020
Statut: epublish

Résumé

The coronavirus disease 2019 (COVID-19) has emerged as a global health and economic security threat with staggering cumulative incidence worldwide. Given the severity of projections, hospitals across the globe are creating additional critical care surge capacity and limiting patient routine access to care for other diseases like tuberculosis (TB). The outbreak fuels panic in sub-Saharan Africa where the healthcare system is fragile in withstanding the disease. Here, we looked over the COVID-19 containment measures in Ethiopia in context from reliable sources and put forth recommendations that leverage the health system response to COVID-19 and TB. Ethiopia shares a major proportion of the global burden of infectious diseases, while the patterns of COVID-19 are still at an earlier stage of the epidemiology curve. The Ethiopian government exerted tremendous efforts to curb the disease. It limited public gatherings, ordered school closures, directed high-risk civil servants to work from home, and closed borders. It suspended flights to 120 countries and restricted mass transports. It declared a five-month national state of emergency and granted a pardon for 20 402 prisoners. It officially postponed parliamentary and presidential elections. It launched the 'PM Abiy-Jack Ma initiative', which supports African countries with COVID-19 diagnostics and infection prevention and control commodities. It expanded its COVID-19 testing capacity to 38 countrywide laboratories. Many institutions are made available to provide clinical care and quarantine. However, the outbreak still has the potential for greater loss of life in Ethiopia if the community is unable to shape the regular behavioral and sociocultural norms that would facilitate the spread of the disease. The government needs to keep cautious that irregular migrants would fuel the disease. A robust testing capacity is needed to figure out the actual status of the disease. The pandemic has reduced TB care and research activities significantly and these need due attention. Ethiopia took several steps to detect, manage, and control COVID-19. More efforts are needed to increase testing capacity and bring about behavioral changes in the community. The country needs to put in place alternative options to mitigate interruptions of essential healthcare services and scientific researches of significant impact.

Sections du résumé

BACKGROUND BACKGROUND
The coronavirus disease 2019 (COVID-19) has emerged as a global health and economic security threat with staggering cumulative incidence worldwide. Given the severity of projections, hospitals across the globe are creating additional critical care surge capacity and limiting patient routine access to care for other diseases like tuberculosis (TB). The outbreak fuels panic in sub-Saharan Africa where the healthcare system is fragile in withstanding the disease. Here, we looked over the COVID-19 containment measures in Ethiopia in context from reliable sources and put forth recommendations that leverage the health system response to COVID-19 and TB.
MAIN TEXT METHODS
Ethiopia shares a major proportion of the global burden of infectious diseases, while the patterns of COVID-19 are still at an earlier stage of the epidemiology curve. The Ethiopian government exerted tremendous efforts to curb the disease. It limited public gatherings, ordered school closures, directed high-risk civil servants to work from home, and closed borders. It suspended flights to 120 countries and restricted mass transports. It declared a five-month national state of emergency and granted a pardon for 20 402 prisoners. It officially postponed parliamentary and presidential elections. It launched the 'PM Abiy-Jack Ma initiative', which supports African countries with COVID-19 diagnostics and infection prevention and control commodities. It expanded its COVID-19 testing capacity to 38 countrywide laboratories. Many institutions are made available to provide clinical care and quarantine. However, the outbreak still has the potential for greater loss of life in Ethiopia if the community is unable to shape the regular behavioral and sociocultural norms that would facilitate the spread of the disease. The government needs to keep cautious that irregular migrants would fuel the disease. A robust testing capacity is needed to figure out the actual status of the disease. The pandemic has reduced TB care and research activities significantly and these need due attention.
CONCLUSIONS CONCLUSIONS
Ethiopia took several steps to detect, manage, and control COVID-19. More efforts are needed to increase testing capacity and bring about behavioral changes in the community. The country needs to put in place alternative options to mitigate interruptions of essential healthcare services and scientific researches of significant impact.

Identifiants

pubmed: 32938497
doi: 10.1186/s40249-020-00753-9
pii: 10.1186/s40249-020-00753-9
pmc: PMC7492795
doi:

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

131

Subventions

Organisme : FIC NIH HHS
ID : D43 TW009127
Pays : United States
Organisme : Medical Research Council
ID : MR/M025470/1
Pays : United Kingdom
Organisme : FIC NIH HHS
ID : D43TW009127
Pays : United States

Références

PLoS One. 2019 Nov 13;14(11):e0224277
pubmed: 31721767
Infect Dis Poverty. 2020 Jul 16;9(1):96
pubmed: 32678037
J Clin Tuberc Other Mycobact Dis. 2020 Mar 05;19:100158
pubmed: 32258437
Lancet Respir Med. 2020 Jun;8(6):536-538
pubmed: 32220280
BMJ Open. 2020 Jun 16;10(6):e035272
pubmed: 32554739
Nat Med. 2020 Jun;26(6):811-812
pubmed: 32398877
Int J Tuberc Lung Dis. 2020 Jun 1;24(6):643-645
pubmed: 32553005
Int J Tuberc Lung Dis. 2020 May 1;24(5):550-552
pubmed: 32398216
Trop Med Health. 2020 May 13;48:32
pubmed: 32425653
Ann Clin Microbiol Antimicrob. 2020 May 23;19(1):21
pubmed: 32446305
Int J Tuberc Lung Dis. 2020 May 1;24(5):542-544
pubmed: 32398211
Trials. 2020 May 5;21(1):383
pubmed: 32370774
S Afr Med J. 2020 Mar 27;110(5):341-342
pubmed: 32657710

Auteurs

Hussen Mohammed (H)

Addis Ababa University, College of Health Sciences, Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), P.O Box 9086, Addis Ababa, Ethiopia. hus.aliya@gmail.com.
Department of Public Health, College of Medicine and Health Sciences, Dire Dawa University, Dire Dawa, Ethiopia. hus.aliya@gmail.com.

Lemessa Oljira (L)

School of Public Health, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia.

Kedir Teji Roba (KT)

School of Nursing and Midwifery, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia.

Getnet Yimer (G)

Addis Ababa University, College of Health Sciences, Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), P.O Box 9086, Addis Ababa, Ethiopia.
Ohio State Global One Health Initiative, Office of International Affairs, The Ohio State University, Addis Ababa, Ethiopia.

Abebaw Fekadu (A)

Addis Ababa University, College of Health Sciences, Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), P.O Box 9086, Addis Ababa, Ethiopia.
Global Health and Infection Department, Brighton and Sussex Medical School, Brighton, UK.

Tsegahun Manyazewal (T)

Addis Ababa University, College of Health Sciences, Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), P.O Box 9086, Addis Ababa, Ethiopia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH